Company Focus
Icon
Latest Icon News
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Related News
Insights
Company Spotlight
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Latest News & Features of interest to Icon
Biotechnology
US biotech Regenxbio has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) RGX-111 and is on track for potential US Food and Drug Administration (FDA) approval via accelerated approval in second-half 2025. 15 March 2025
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. 14 March 2025
Biotechnology
Innovent Biologics has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED).
The National Medical Products Administration (NMPA) cleared the treatment, making it the second IGF-1R antibody therapy approved globally. 14 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 US flu season following a thorough and comprehensive review of US and global surveillance data. 14 March 2025
Biotechnology
Sutro Biopharma, a US biotechnology company, has announced significant organizational changes, including a workforce reduction of nearly 50%, a shift in its drug development focus, and leadership transitions. 14 March 2025
Pharmaceutical
Swiss drugmaker Idorsia has announced the publication of a Phase IV study in the Journal of Sleep Research. 14 March 2025
Biotechnology
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Biotechnology
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Biotechnology
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today announced a research and license agreement with German family-owned pharma major Boehringer Ingelheim to accelerate the development of multiple drug targets. 13 March 2025
Biotechnology
Prague headquartered clinical-stage SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix, a Lonza company, to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. 13 March 2025
Latest In Brief for Icon
Pharmaceutical
Israel-based radiopharma company Isotopia has launched Isoprotrace in Germany, supported by distribution partner DSD Pharma. 10 March 2025
Latest Relevant Ones To Watch News
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
11 March 2025
10 March 2025
26 February 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze